Mesa Laboratories (MLAB)
(Delayed Data from NSDQ)
$118.79 USD
-2.00 (-1.66%)
Updated Sep 10, 2024 04:00 PM ET
After-Market: $118.32 -0.47 (-0.40%) 5:14 PM ET
1-Strong Buy of 5 1
B Value A Growth B Momentum A VGM
Balance Sheet
Fiscal Year End for Mesa Laboratories, Inc falls in the month of March.
All items in Millions except Per Share data.
3/31/2024 | 3/31/2023 | 3/31/2022 | 3/31/2021 | 3/31/2020 | |
---|---|---|---|---|---|
Assets | |||||
Cash & Equivalents | 28 | 33 | 49 | 264 | 81 |
Receivables | 39 | 43 | 41 | 24 | 21 |
Notes Receivable | NA | 0 | 0 | 0 | 0 |
Inventories | 33 | 35 | 25 | 11 | 14 |
Other Current Assets | 9 | 9 | 9 | 5 | 6 |
Total Current Assets | 109 | 119 | 124 | 304 | 123 |
Net Property & Equipment | 32 | 28 | 29 | 22 | 22 |
Investments & Advances | NA | 0 | 0 | 0 | 0 |
Other Non-Current Assets | NA | 0 | 0 | 0 | 0 |
Deferred Charges | 1 | 1 | 1 | 1 | 11 |
Intangibles | 294 | 503 | 541 | 273 | 261 |
Deposits & Other Assets | 11 | 10 | 12 | 3 | 2 |
Total Assets | 447 | 662 | 707 | 601 | 420 |
Liabilities & Shareholders Equity | 3/31/2024 | 3/31/2023 | 3/31/2022 | 3/31/2021 | 3/31/2020 |
---|---|---|---|---|---|
Notes Payable | NA | 0 | 0 | 0 | 0 |
Accounts Payable | 6 | 6 | 8 | 4 | 3 |
Current Portion Long-Term Debt | NA | 0 | 0 | 0 | 0 |
Current Portion Capital Leases | NA | 0 | 0 | 0 | 0 |
Accrued Expenses | 23 | 23 | 26 | 18 | 15 |
Income Taxes Payable | NA | 0 | 0 | 2 | 0 |
Other Current Liabilities | 15 | 14 | 14 | 9 | 7 |
Total Current Liabilities | 44 | 43 | 48 | 33 | 26 |
Mortgages | NA | 0 | 0 | 0 | 0 |
Deferred Taxes/Income | 20 | 34 | 39 | 16 | 33 |
Convertible Debt | 171 | 170 | 169 | 146 | 140 |
Long-Term Debt | 51 | 13 | 49 | 0 | 0 |
Non-Current Capital Leases | NA | 0 | 0 | 0 | 0 |
Other Non-Current Liabilities | 16 | 8 | 8 | 1 | 1 |
Minority Interest (Liabilities) | NA | 0 | 0 | 0 | 0 |
Total Liabilities | 301 | 268 | 314 | 195 | 200 |
Shareholders Equity | 3/31/2024 | 3/31/2023 | 3/31/2022 | 3/31/2021 | 3/31/2020 |
---|---|---|---|---|---|
Preferred Stock | NA | 0 | 0 | 0 | 0 |
Common Stock (Par) | 344 | 332 | 313 | 318 | 158 |
Capital Surplus | NA | 0 | 0 | 0 | 0 |
Retained Earnings | -183 | 74 | 77 | 72 | 72 |
Other Equity | -15 | -13 | 4 | 16 | -10 |
Treasury Stock | NA | 0 | 0 | 0 | 0 |
Total Shareholder's Equity | 145 | 393 | 394 | 406 | 220 |
Total Liabilities & Shareholder's Equity | 447 | 662 | 707 | 601 | 420 |
Total Common Equity | 100,144 | 393 | 394 | 406 | 220 |
Shares Outstanding | 5.30 | 5.30 | 5.20 | 5.10 | 4.30 |
Book Value Per Share | 18,895.17 | 74.24 | 75.73 | 79.65 | 51.17 |
Fiscal Year End for Mesa Laboratories, Inc falls in the month of March.
All items in Millions except Per Share data.
6/30/2024 | 3/31/2024 | 12/31/2023 | 9/30/2023 | 6/30/2023 | |
---|---|---|---|---|---|
Assets | |||||
Cash & Equivalents | 28 | -99,971 | 28 | 36 | 32 |
Receivables | 36 | 39 | 36 | 36 | 36 |
Notes Receivable | 0 | NA | 0 | 0 | 0 |
Inventories | 32 | 33 | 36 | 33 | 36 |
Other Current Assets | 11 | 9 | 18 | 13 | 11 |
Total Current Assets | 107 | 109 | 118 | 118 | 115 |
Net Property & Equipment | 31 | 32 | 32 | 29 | 28 |
Investments & Advances | 0 | NA | 0 | 0 | 0 |
Other Non-Current Assets | 0 | NA | 0 | 0 | 0 |
Deferred Charges | 1 | 1 | 1 | 1 | 1 |
Intangibles | 289 | 294 | 579 | 481 | 489 |
Deposits & Other Assets | 12 | 11 | 12 | 9 | 10 |
Total Assets | 440 | 447 | 742 | 637 | 643 |
Liabilities & Shareholders Equity | 6/30/2024 | 3/31/2024 | 12/31/2023 | 9/30/2023 | 6/30/2023 |
---|---|---|---|---|---|
Notes Payable | 0 | NA | 0 | 0 | 0 |
Accounts Payable | 6 | 6 | 5 | 5 | 6 |
Current Portion Long-Term Debt | 4 | NA | 0 | 0 | 0 |
Current Portion Capital Leases | 0 | NA | 0 | 0 | 0 |
Accrued Expenses | 31 | 23 | 25 | 21 | 18 |
Income Taxes Payable | 0 | NA | 0 | 0 | 0 |
Other Current Liabilities | 15 | 15 | 14 | 14 | 15 |
Total Current Liabilities | 55 | 44 | 44 | 40 | 39 |
Mortgages | 0 | NA | 0 | 0 | 0 |
Deferred Taxes/Income | 20 | 20 | 44 | 33 | 34 |
Convertible Debt | 97 | 171 | 171 | 171 | 171 |
Long-Term Debt | 112 | 51 | 62 | 0 | 5 |
Non-Current Capital Leases | 0 | NA | 0 | 0 | 0 |
Other Non-Current Liabilities | 7 | 17 | 5 | 7 | |
Minority Interest (Liabilities) | 0 | NA | 0 | 0 | 0 |
Total Liabilities | 290 | 301 | 339 | 249 | 255 |
Shareholders Equity | 6/30/2024 | 3/31/2024 | 12/31/2023 | 9/30/2023 | 6/30/2023 |
---|---|---|---|---|---|
Preferred Stock | 0 | NA | 0 | 0 | 0 |
Common Stock (Par) | 346 | 344 | 341 | 338 | 334 |
Capital Surplus | 0 | NA | 0 | 0 | 0 |
Retained Earnings | -181 | -183 | 72 | 71 | 73 |
Other Equity | -14 | -15 | -10 | -21 | -19 |
Treasury Stock | 0 | NA | 0 | 0 | 0 |
Total Shareholder's Equity | 151 | 145 | 403 | 388 | 388 |
Total Liabilities & Shareholder's Equity | 440 | 447 | 742 | 637 | 643 |
Total Common Equity | 151 | 100,144 | 403 | 388 | 388 |
Shares Outstanding | 5.40 | 5.30 | 5.30 | 5.30 | 5.30 |
Book Value Per Share | 27.91 | 18,895.17 | 76.03 | 73.16 | 73.15 |